98%
921
2 minutes
20
Introduction: Cervical cancer screening uptake among East African immigrants in the U.S. is low. Offering self-collected samples for human papillomavirus (HPV) testing increases screening coverage among underserved populations, but the potential impact on cervical cancer incidence and mortality is understudied.
Methods: A Markov cohort state-transition model was used to predict the impact of primary HPV screening with self-sampling on cervical cancer incidence and mortality among East African immigrant women in Washington state. The model estimated cervical cancer cases and deaths for a hypothetical cohort from ages 25 to 80 years under alternative screening, diagnostic colposcopy and treatment scenarios. Base case scenarios compared primary HPV testing by clinician-sampling exclusively (standard of care) with self-sampling exclusively, assuming higher screening coverage (70% vs 63%) but lower colposcopy adherence with self-sampling (67% vs 83%) with equal treatment coverage of 85%, based on Washington state patient data. Sensitivity analyses with varied coverages, and also the combinations of the 2 strategies were evaluated. The model was developed and fitted between 2022 and 2024.
Results: In the base case scenario, an exclusive self-sampling strategy results in 4% higher cervical cancer incidence and mortality compared to the standard of care. Self-sampling results in lower cancer incidence and mortality if colposcopy adherence is raised to the level of the standard of care and/or if coverage is increased beyond 90%. In scenarios combining clinician- with self-sampling, the benefits of reaching more women with self-sampling are attenuated if more than 34% of screening is done by self-sampling.
Conclusions: Self-sampling has the potential to improve cervical cancer prevention for underserved populations. The impact of the strategy can be enhanced with stronger linkage to follow-up care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amepre.2024.11.012 | DOI Listing |
Obstet Gynecol
July 2025
Ana I. Tergas is from the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Health, Rutgers New Jersey Medical School, Newark, New Jersey. Mark H. Einstein is from the Department of Obstetrics, Gynecology, and Women's Health, Albert Einstein College of Medicine
Clin Transl Oncol
September 2025
Ophthalmology Unit, Cannizzaro Hospital, 95126, Catania, Italy.
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life.
View Article and Find Full Text PDFMed Oncol
September 2025
Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
Gynecological cancer, encompassing cancers such as endometrial and cervical cancer, is a growing concern worldwide, with a rising incidence and significant impact on women's health. Pterostilbene (PT), a natural compound, has shown promising therapeutic potential in gynecological cancer treatment. This review aims to summarize the current state of knowledge on PT's effects in gynecological cancer, focusing on its molecular mechanisms, preclinical studies, and clinical trials.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2025
Cancer Treatment and Nuclear Cardiology Department, Al Azhar University, Cairo, Egypt.
Background: High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, China.
Human papillomavirus (HPV) causes multiple diseases in both sexes. This study evaluates the cost-effectiveness and epidemiological impact - defined as reductions in HPV-related disease cases - of a gender-neutral vaccination (GNV) strategy in China's economically developed metropolises: Beijing, Shanghai, and Guangzhou. A discrete-time Markov model simulated no vaccination, female-only vaccination (FOV), and GNV strategies among 12-year-olds.
View Article and Find Full Text PDF